Actively Recruiting
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Led by M.D. Anderson Cancer Center · Updated on 2026-04-13
24
Participants Needed
3
Research Sites
415 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
C
Cannonball Kids' Cancer Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
CONDITIONS
Official Title
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 3 years or older and younger than 22 years
- Pathologically confirmed malignant cerebellar brain tumor that is recurrent or progressive despite standard treatments
- Tumor lesion size between 1.0 cm and 3.0 cm in diameter and accessible by surgery
- Fully recovered from acute toxicities of prior chemotherapy, immunotherapy, or radiotherapy
- Last dose of myelosuppressive chemotherapy at least 3 weeks prior (6 weeks if nitrosurea)
- Last dose of investigational or biologic agents at least 7 days prior; for viral therapy, at least 3 months prior
- Last dose of monoclonal antibodies at least 21 days prior
- Last craniospinal radiation or total body irradiation at least 3 months prior; focal or palliative radiation at least 28 days prior
- At least 3 months since autologous bone marrow transplant
- Normal blood, kidney, and liver function based on specified laboratory values
- Performance score of at least 60 (Modified Lansky for under 16 years, Karnofsky for 16 years or older)
- Life expectancy of at least 8 weeks
- Written informed consent obtained from patient or legal guardian
You will not qualify if you...
- Treatments outside allowed guidelines
- Diffuse tumor affecting 3 or more brain lobes
- Acute infection, low white blood cell count, or other conditions preventing surgery
- Pregnancy or breastfeeding
- Recent or ongoing encephalitis, CNS infection, or multiple sclerosis treatment within 3 months
- Tumor involvement requiring ventricular or brainstem inoculation or access through ventricle
- Steroid dose increase within 1 week prior or daily dexamethasone dose over 2 mg
- Known HIV positive status
- Concurrent use of antiviral drugs active against HSV or immunosuppressive drugs (except certain steroids)
- Presence of other current cancers
- Concurrent anticancer or investigational drug treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Children's of Alabama
Birmingham, Alabama, United States, 35233
Active, Not Recruiting
2
St. Louis Children's Hospital
St Louis, Missouri, United States, 63110
Active, Not Recruiting
3
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
K
Kara Kachurak, CRNP
CONTACT
G
Gregory K Friedman, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here